9
Jun
2020

Versant Bets $50M on Lycia to Make Protein Degraders Against Extracellular Targets

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Red Tree Debuts With $272M, Zeroing In On West Coast Startups
Versant-backed Cimeio Gets $50M for Shielded Stem Cell Therapies
Versant, OrbiMed Invest $50M in Startup Inserting Genes in the Liver
Versant, RA Bet $47M on LENZ Therapeutics to Restore Near Vision in Middle Age